| Patents for C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies (149,320) |
|---|
| 04/15/2004 | US20040071695 Novel g-protein coupled receptor |
| 04/15/2004 | US20040071694 Erythropoietin receptor binding antibodies |
| 04/15/2004 | US20040071693 Humanised antibodies |
| 04/15/2004 | US20040071692 Minimizes toxicity to normal tissue; high therapeutic index |
| 04/15/2004 | US20040071690 High avidity polyvalent and polyspecific reagents |
| 04/15/2004 | US20040071632 Determining plaque location using human monoclonal antibody fragment cloned by phage display that binds specifically to oxidized forms of low density lipoproteins |
| 04/15/2004 | CA2501091A1 Amyloid beta-derived diffusible ligands (addls), addl-surrogates, addl-binding molecules, and uses thereof |
| 04/15/2004 | CA2500978A1 Antibodies and cyclic peptides which bind cea (carcinoembryonic antigen) and their use as cancer therapeutics |
| 04/15/2004 | CA2500895A1 Peptide-based passive immunization therapy for treatment of atherosclerosis |
| 04/15/2004 | CA2500883A1 Mouse-origin proteins forming domain or use thereof |
| 04/15/2004 | CA2500669A1 Products for regulating the degradation of collagen and methods for identifying same |
| 04/15/2004 | CA2500652A1 Diagnosis and monitoring of diseases |
| 04/15/2004 | CA2500596A1 Anti-tsg101 antibodies and their uses for treatment of viral infections |
| 04/15/2004 | CA2499891A1 Multimeric protein engineering |
| 04/15/2004 | CA2498854A1 Novel mhc ii associated peptides |
| 04/15/2004 | CA2498829A1 Use of protein tyrosine phosphatase inhibitors for prevention and/or treatment of cancer |
| 04/15/2004 | CA2498631A1 Use of a33 antigens and jam-it |
| 04/15/2004 | CA2484335A1 Use of molecules which interact with the haptoglobin receptor ligand binding |
| 04/14/2004 | EP1408333A2 Diagnosis and treatment of Alzheimer's disease |
| 04/14/2004 | EP1408113A1 Human type antihuman ige receptor antibody and antibody fragment |
| 04/14/2004 | EP1408112A1 MONOCLONAL ANTIBODY BINDING TO MT4−MMP CATALYTIC DOMAIN |
| 04/14/2004 | EP1408049A2 A novel inositol 1,4,5-trisphosphate (IP3) receptor-binding protein and an IP3 indicator |
| 04/14/2004 | EP1407781A1 Anti-lymphotoxin-beta receptor antibodies as anti-tumor agents |
| 04/14/2004 | EP1407269A2 A method for diagnosing a person having multiple sclerosis |
| 04/14/2004 | EP1407019A2 Intestinal proteins |
| 04/14/2004 | EP1407017A2 Human tumor necrosis factor receptor |
| 04/14/2004 | EP1407015A2 Compositions and methods relating to breast specific genes and proteins |
| 04/14/2004 | EP1407014A2 Screening method for attenuating or virulence defective microbial cells |
| 04/14/2004 | EP1407013A1 Mutations in ion channels |
| 04/14/2004 | EP1407009A2 Hydrolase enzymes and their use in kinetic resolution |
| 04/14/2004 | EP1406931A2 Modification of human variable domains |
| 04/14/2004 | EP1406930A2 Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof |
| 04/14/2004 | EP1406929A2 Glycoprotein vi fusion proteins |
| 04/14/2004 | EP1406928A1 Ntb-a, a surface molecule involved in natural killer cells activity |
| 04/14/2004 | EP1406925A2 Survivin interacting protein tpr1 |
| 04/14/2004 | EP1406923A2 Histidine phosphatase interacting protein with 180kd |
| 04/14/2004 | EP1406916A2 Genes associated with mechanical stress, expression products therefrom, and uses thereof |
| 04/14/2004 | EP1406658A1 Liquid formulation comprising cetuximab and a fatty acid ester of polyoxyethylene sorbitan |
| 04/14/2004 | EP1406657A1 A novel engineered superantigen for human therapy |
| 04/14/2004 | EP1406656A2 METHODS OF ADMINISTERING ANTI-TNF$g(a) ANTIBODIES |
| 04/14/2004 | EP1406653A2 T cell regulatory genes and methods of use thereof |
| 04/14/2004 | EP1406644A2 Modified proteins, designer toxins, and methods of making thereof |
| 04/14/2004 | EP1406638A2 Macrophage receptor agonist or antagonist |
| 04/14/2004 | EP1406636A2 System and method for the large scale labeling of compounds with radiohalogens |
| 04/14/2004 | EP1406493A1 Administration of agents via the pept-2 transporter |
| 04/14/2004 | EP0765392B1 Interleukin-5 specific recombinant antibodies |
| 04/14/2004 | CN1489628A Compounds and methods for treatment and diagnosis of chlamydial infection |
| 04/14/2004 | CN1489474A Monoclonal antibodies to CLFA protein and method of use in treating or preventing |
| 04/14/2004 | CN1489473A Silensed anti-CD 28 antibodies and use thereof |
| 04/14/2004 | CN1488646A SARS virus S protein and N protein fusion protein, and preparation and use thereof |
| 04/14/2004 | CN1488645A Specific antibody IgY for anti SARS virus, and preparing method thereof and composition containing same and its use |
| 04/14/2004 | CN1145798C In vitro method for determining presence of hepatocellular carcindoma |
| 04/14/2004 | CN1145642C Method for separating and/or isolating plasma proteins by annularchromatography |
| 04/14/2004 | CN1145639C Subunit respiratory syncytial virus vaccine preparation |
| 04/13/2004 | US6720409 Anti-human influenza virus antibody |
| 04/13/2004 | US6720181 Ubiquitin ligases as therapeutic targets |
| 04/13/2004 | US6720166 Non-a, non-b, non-c, non-c, non-d, non-e hepatitis reagents and methods for their use |
| 04/13/2004 | US6720165 Generation of preferential immunoglobulin; obtain glycosylated antibody, deglycosylate, expose to enzymatic splitting, recover immunoglobulin |
| 04/13/2004 | US6720159 88KDA tumorigenic growth factor and antagonists |
| 04/13/2004 | US6720156 Monoclonal antibody; for use in the treatment, diagnosis, screening, and imaging of joint defects |
| 04/13/2004 | US6720155 Monoclonal antibody inhibitor of GM-CSF, IL-3, IL-5 and other cytokines, and uses thereof |
| 04/13/2004 | US6720146 Nucleotide sequences coding polypeptide for use in the treatment, diagnosis and prevention of ovarian cancer |
| 04/13/2004 | US6719978 Virus-like particles for the induction of autoantibodies |
| 04/13/2004 | US6719975 Immunogenic polymerized hirudin in the absence of carrier protein; vaccines |
| 04/13/2004 | US6719972 Induce antigen specific apoptosis in activated t cells; ligands with monoclonal anti-ctla4 antibody that binds to an epitope of ctla4 |
| 04/13/2004 | US6719971 Method for making humanized antibodies |
| 04/13/2004 | CA2195076C Process for modifying the stability of antibodies |
| 04/11/2004 | CA2403313A1 Potent t cell modulating molecules |
| 04/08/2004 | WO2004029630A1 N-11 truncated amyloid-beta monoclonal antibodies, compositions, methods and uses |
| 04/08/2004 | WO2004029629A1 N-11 truncated amyloid-beta nomoclonal antibodies, compositions, methods and uses |
| 04/08/2004 | WO2004029622A2 Antibody tools for the diagnostic use in the medical therapy with inhibitors of histone deacetylases |
| 04/08/2004 | WO2004029583A2 Methods of secretory vimentin detection and modulation |
| 04/08/2004 | WO2004029575A2 Methods for diagnosing htlv-i-mediated diseases |
| 04/08/2004 | WO2004029287A2 Polypeptides and nucleic acids encoding these and their use for the prevention, diagnosis or treatment of liver disorders and epithelial cancer |
| 04/08/2004 | WO2004029284A2 Efficient generation of stable expression cell lines through the use of scorable homeostatic reporter genes |
| 04/08/2004 | WO2004029249A1 Immunoglobulin compositions and methods |
| 04/08/2004 | WO2004029244A1 Animal cells having chimeric receptor and utilization thereof |
| 04/08/2004 | WO2004029242A1 Antibody against enzyme specifically cleaving von villebrand factor and assay system using the same |
| 04/08/2004 | WO2004029234A1 Bhyd gene |
| 04/08/2004 | WO2004029214A2 Lfa-1 alpha subunit antibodies and methods of use |
| 04/08/2004 | WO2004029208A2 Cell separation compositions and methods |
| 04/08/2004 | WO2004029207A2 Optimized fc variants and methods for their generation |
| 04/08/2004 | WO2004029206A2 Targeted cd1d molecules |
| 04/08/2004 | WO2004029094A1 Monoclonal antibody specific for human mitochondrial adenylate kinase isozyme 3 |
| 04/08/2004 | WO2004029093A2 Humanized anti-granulocyte mn-3 antibody and uses thereof |
| 04/08/2004 | WO2004029092A2 Antibody for adcc and inducing cytokine production |
| 04/08/2004 | WO2004029069A2 Hybridomas producing high levels of human sequence antibody |
| 04/08/2004 | WO2004028565A1 Methods for alleviating symptoms associated with neuropathic conditions comprising administration of low levels of antibodies |
| 04/08/2004 | WO2004028564A2 Treatment of pathologies which escape the immune response, using optimised antibodies |
| 04/08/2004 | WO2004028558A1 Preventives/remedies for neurodegenerative disease |
| 04/08/2004 | WO2004028555A1 Resistin binding proteins, their preparation and use |
| 04/08/2004 | WO2004028479A2 Nouvelles compositions et methodes de traitement du psoriasis |
| 04/08/2004 | WO2004028473A2 Synergistic compositions for the prevention and treatment of acquired immunodeficiency syndrome |
| 04/08/2004 | WO2004028259A2 A method for stabilizing bioactive molecules |
| 04/08/2004 | WO2004017992A3 Ptk7 protein involvement in carcinoma |
| 04/08/2004 | WO2004014952A3 Specific probnp(1-108) antibodies for diagnosing heart failure |
| 04/08/2004 | WO2004013172A3 Fragments of beta-amyloid as targets for vaccination against alzheimer disease |
| 04/08/2004 | WO2004005350A3 Mutant fab fragments of the chimeric 13b8.2 anti-cd4 antibody and uses thereof |
| 04/08/2004 | WO2004001069A3 Compositions and methods for detecting pathologies affecting neuromuscular transmission |
| 04/08/2004 | WO2004001004A3 Membrane associated tumor endothelium markers |